Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
C8C8
- Development stage
- Preclinical
- Lead developer
- EsoCap
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Esophageal
01
Overview
C8C8 is an anti-BMP (Bone Morphogenetic Protein) monoclonal antibody being developed by EsoCap, under an exclusive worldwide licensing agreement with Upadia. It has demonstrated preclinical efficacy in inhibiting the development of Barrett's esophagus. EsoCap plans to combine C8C8 with its proprietary thin-film drug delivery platform to enable prolonged, local application directly to the esophagus, aiming to provide a non-invasive treatment for this pre-cancerous condition.
02
Targets
BMP2 (Bone morphogenetic protein 2)BMP4 (Bone morphogenetic protein 2)
Beyond the preview
Go deeper on C8C8.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on C8C8.